Omada Health (OMDA) CFO Steven Cook Sells $656K of Stock

Omada Health Stock Trades Near $21.95 Ahead of Autumn Earnings

Omada Health, Inc. (NasdaqGS: OMDA) shares change hands around $21.95 on Wednesday, holding well above the 200-day moving average of $17.09 and below the 52-week peak of $26.91. The virtual healthcare provider carries a trailing price-to-earnings ratio of 30.76 and a forward P/E of 37.06. Investors tracking the health information services sector look forward to the company's upcoming earnings release scheduled for November 5, 2026, which will offer new details on cardiometabolic program expansion and revenue trends.

Chief Financial Officer Steven Cook Sells 33000 Shares

Chief Financial Officer Steven Cook executed a planned sale of 33,000 shares on June 26, 2026, at an average price of $19.89. The transaction totaled $656,370 and was set up ahead of time through a pre-arranged program. This follows an earlier June sale by the same executive, when Cook parted with 2,600 shares on June 24, 2026, at $19.02 for a total of $49,452.

Busy Month of Executive Stock Transactions at Omada Health

Executive equity adjustments kept a steady pace through June across the South San Francisco enterprise. Chief Accounting Officer Craig Gracey sold 2,083 shares on June 24, 2026, at $19.01, bringing in $39,597.83, following an earlier disposition of 6,894 shares on June 12, 2026, at $17.42. Chief Executive Officer Sean Duffy also completed a planned sale on June 24, 2026, disposing of 2,800 shares at $19.01 for $53,228. On the buying side, Adam Stavisky acquired 10,882 shares on June 16, 2026, with no cash value reported for that acquisition.

Wall Street Analysts Maintain Buy Ratings and Targets

Financial firms continue updating their outlooks on the healthcare provider with generally positive stances. On October 14, 2026, Freedom Capital Markets maintained its buy rating alongside a $35.00 price target, matching its earlier stance from September 14, 2026. Barclays kept an overweight rating on September 11, 2026, while raising its target to $27.00 from $25.00. Needham reiterated a buy rating with a $28.00 target on the same day, while BTIG reaffirmed a buy rating and a $35.00 target. Earlier in August, JP Morgan maintained an overweight rating and lifted its target to $30.00, Citizens kept a market outperform rating with a $32.00 target, and Baird maintained a neutral rating with a $25.00 target.

Virtual Care Programs and Corporate Growth

Omada Health operates a virtual care platform focused on cardiometabolic health, physical therapy, weight management, and behavioral support. The enterprise delivers its programs to employers, health plans, and pharmacy benefits managers across the United States. These digital care offerings aim to address chronic conditions through remote monitoring and coaching, supporting clinical outcomes for members dealing with prediabetes, hypertension, and musculoskeletal issues.

Looking Ahead to November Financial Reports

Shareholders turn their attention toward the upcoming earnings report slated for November 5, 2026, for fresh updates on revenue expansion and operating margins. Regulatory filings will continue to record any further equity movements by corporate officers, providing insight into executive holdings as the firm moves through the final quarter of the year.